MedTrace Logo

A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young Women

NCT00800618 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2010-02-10

No results posted yet for this study

Summary

The study will investigate how well multiple doses of PF-02413873 are tolerated by healthy young women, how the body handles multiple doses of PF-02413873 and which effect PF-02413873 has on sex hormones in healthy young women

Conditions

  • Endometriosis

Interventions

DRUG

PF-02413873 100 mg QD

100 mg of PF-02413873 oral suspension once daily for 14 days

DRUG

PF-02413873 1500 mg QD

1500 mg of PF-02413873 oral suspension once daily for 14 days

DRUG

PF-02413873 20 mg QD

20 mg of PF-02413873 oral suspension once daily for 14 days

DRUG

PF-02413873 500 mg QD

500 mg of PF-02413873 oral suspension once daily for 14 days

DRUG

PF-02413873 Placebo

PF-0241383 Placebo once daily for 14 days

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States
  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00800618 on ClinicalTrials.gov